Core Viewpoint - China Tongfu (01763.HK) announced that its subsidiary, Atomic High-Tech Co., has successfully achieved the domestic large-scale production of the radioactive nuclide Gallium-68 (Ge-68) using a 30MeV proton cyclotron, meeting commercial product standards in Europe and the U.S. This development signifies China's capability for stable and independent production of Ge-68, which is crucial for precise diagnosis and treatment of cancer patients [1][2]. Group 1 - Atomic High-Tech has become one of the few companies globally to master the large-scale preparation technology of Ge-68, which is the parent nuclide of Gallium-68 [1]. - Gallium-68 labeled radiopharmaceuticals are essential in nuclear medicine for PET imaging, providing significant support for clinical diagnosis and treatment of tumors [1]. - There are currently 13 Gallium-68 drugs in clinical trials in China, with several foreign counterparts already approved for cancer diagnosis, indicating a broad market potential for Ge-68 [1]. Group 2 - The company plans to continue focusing on the nuclear medicine field, increasing investment in the research and development of radiopharmaceuticals and technological innovation to support the development of precision medicine [2]. - The commitment to enhancing product quality and services aims to strengthen healthcare for the public [2].
中国同辐(01763.HK)附属原子高科首次实现放射性核素锗-68的国产规模化制备